Search Results - "de Boer, Antonius"

Regulatory scientific advice on non-inferiority drug trials by Wangge, Grace, Putzeist, Michelle, Knol, Mirjam J, Klungel, Olaf H, Gispen-De Wied, Christine C, de Boer, Antonius, Hoes, Arno W, Leufkens, Hubert G, Mantel-Teeuwisse, Aukje K

“…The active-controlled trial with a non-inferiority design has gained popularity in recent years. However, non-inferiority trials present some methodological…”
Get full text

The Effect of Eighteen-Month Metformin Treatment in Obese Adolescents: Comparison of Results Obtained in Daily Practice with Results from a Clinical Trial by Knibbe, C. A. J., de Boer, A., van de Garde, Ewoudt M. W., Hoving, Vera, van der Aa, M. P., van der Vorst, M. M. J.

“…Background. In a recent randomized controlled trial (RCT) in obese adolescents, 18 month-treatment with metformin versus placebo was reported to lead to…”
Get full text

Challenges of defining a non-inferiority margin: a case study of non-inferiority randomized controlled trials of oral anti-thrombolytic agents for prophylaxis of venous thromboembolic events after orthopedic surgery by Wangge, Grace, Klungel, Olaf H, Roes, Kit CB, de Boer, Antonius, Hoes, Arno W, Knol, Mirjam J

Get full text

The trade-off between cardiovascular and gastrointestinal effects of rofecoxib by Florentinus, Stefan R., Heerdink, Eibert R., Boer, Antonius de, van Dijk, Liset, Leufkens, Hubert G. M.

“…An Erratum has been published for this article in Pharmacoepidemiology and Drug Safety 14(9), 2005, 669. Background The cyclooxygenase‐2 (COX‐2) inhibitor…”
Get full text

Methodological comparison of marginal structural model, time-varying Cox regression, and propensity score methods: the example of antidepressant use and the risk of hip fracture by Ali, M. Sanni, Groenwold, Rolf H. H., Belitser, Svetlana V., Souverein, Patrick C., Martín, Elisa, Gatto, Nicolle M., Huerta, Consuelo, Gardarsdottir, Helga, Roes, Kit C. B., Hoes, Arno W., de Boer, Antonius, Klungel, Olaf H.

“…Background Observational studies including time‐varying treatments are prone to confounding. We compared time‐varying Cox regression analysis, propensity score…”
Get full text

Differences in interaction and subgroup-specific effects were observed between randomized and nonrandomized studies in three empirical examples by Schmidt, Amand F, Rovers, Maroeska M, Klungel, Olaf H, Hoes, Arno W, Knol, Mirjam J, Nielen, Mirjam, de Boer, Antonius, Groenwold, Rolf H.H

“…Abstract Objective To determine the comparability of subgroup-specific and interaction effects (differences between subgroups) between different study designs…”
Get full text

Drug costs associated with non-adherence to cholesterol management guidelines for primary prevention of cardiovascular disease in an elderly population : The Rotterdam Study by GUMBS, Pearl D, VERSCHUREN, W. M. Monique, MANTEL-TEEUWISSE, Aukje K, DE WIT, Ardine G, HOFMAN, Albert, TRIENEKENS, Paul H, STRICKER, Bruno H. Ch, DE BOER, Antonius, KLUNGEL, Olaf H

“…In The Netherlands, costs of HMG-CoA reductase inhibitor (statin) use have recently increased sharply compared with costs of other drugs. However, several…”
Get full text

The trade-off between cardiovascular and gastrointestinal effects of rofecoxib by Florentinus, Stefan R., Heerdink, Eibert R., Boer, Antonius de, van Dijk, Liset, Leufkens, Hubert G.M.

“…The original article to which this Erratum refers was published in Pharmacoepidemiology and Drug Safety, 14 (7) 2005, 437–441. No …”
Get full text